Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion

Angelini Pharma has agreed to acquire biopharmaceutical company Catalyst Pharmaceuticals for $4.1 billion, or $31.50 per share. The deal was unanimously approved by both boards. Catalyst also resolved patent litigation related to its rare disease drug Firdapse.

05/07/2026, 11:45 AM • Benzinga

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion (€3.5 billion). The acquisition marks Angelini Pharma's entry into the U.S. market and strengthens its focus on brain health and rare diseases. The deal is expected to close in Q3 2026, subject to stockholder approval and regulatory clearances. Catalyst has also resolved patent litigation regarding its FIRDAPSE product.

05/07/2026, 3:25 AM • Benzinga

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

Catalyst Pharmaceuticals and licensor SERB S.A. have settled patent litigation with Hetero Labs regarding generic FIRDAPSE (amifampridine). Under the settlement, Hetero will not market its generic version in the U.S. before January 2035 if approved by the FDA. This resolves all pending FIRDAPSE patent litigation for Catalyst, following similar settlements with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited.

05/07/2026, 2:44 AM • GlobeNewswire

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion (€3.5 billion). The acquisition marks Angelini's entry into the U.S. market and strengthens its focus on brain health and rare diseases. The transaction, unanimously approved by both boards, is expected to close in Q3 2026.

05/07/2026, 2:14 AM • Benzinga

Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount

Catalyst Pharmaceuticals (CPRX) trades at a 20-33% discount to pharma peers with a 7.5% free cash flow yield. The company's valuation is fairly valued to slightly undervalued at $24.50, with probability-weighted fair value around $29. The key binary catalyst is the Hetero litigation outcome expected in 2026—a win could push fair value to $28-32 with mid-teens returns through 2030, while a loss would drop it to $16-20 due to loss of FIRDAPSE patent exclusivity. Insider selling and mixed institutional positioning suggest the market has already priced in execution risks and patent cliff concerns.

03/11/2026, 7:26 AM • Investing

Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, exercised and sold 10,983 shares for approximately $256,200 on November 26, 2025, reducing his direct holdings by roughly 74%. The sale occurred following the company's strong Q3 results with revenues up 17.4% year-over-year and raised full-year guidance. While exercise-and-sell transactions are common for stock compensation management, the magnitude of this stake reduction warrants investor attention despite the company's positive operational momentum.

12/31/2025, 11:06 AM • The Motley Fool

Fünfjahresdaten zu AGAMREE® (Vamorolon) bei Patienten mit DMD zeigen ein verbessertes Sicherheitsprofil bei vergleichbarer Wirksamkeit wie bei der Standardbehandlung mit Kortikosteroiden

Santhera Pharmaceuticals reported positive long-term data for AGAMREE, showing comparable effectiveness to standard corticosteroids in treating Duchenne Muscular Dystrophy, with improved safety profile and reduced side effects like growth suppression and vertebral fractures.

11/04/2025, 1:31 AM • GlobeNewswire

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Long-term study of AGAMREE in Duchenne muscular dystrophy patients reveals comparable effectiveness to standard corticosteroids, with significantly lower rates of vertebral fractures and better growth maintenance over five years.

11/04/2025, 1:31 AM • GlobeNewswire

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Catalyst Pharmaceuticals and SERB S.A. reached a settlement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE, allowing Lupin to market a generic version starting February 2035, with ongoing litigation against Hetero still pending.

08/26/2025, 7:12 PM • GlobeNewswire